Literature DB >> 23832865

Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites.

N van Duinen1, E P M Corssmit, W H A de Jong, D Brookman, I P Kema, J A Romijn.   

Abstract

CONTEXT: A substantial number of patients with head and neck paragangliomas (HNPGLs) have biochemically active tumors, evidenced by increased urinary excretion of catecholamines and metabolites, including 3-methoxytyramine (3MT). It is unclear whether plasma levels of these parameters are more sensitive to detect biochemical activity in HNPGL patients than urinary excretion rates.
OBJECTIVE: To compare plasma free levels vs urinary excretion rates of deconjugated 3MT and combined metanephrines (MNs) in patients with HNPGL. PATIENTS AND METHODS: We included 124 consecutive patients with HNPGL for screening of catecholamine excess by measurement of 24-h urinary excretion rates of deconjugated (nor)metanephrine, (nor)epinephrine, dopamine, vanillylmandelic acid, 3MT, and plasma free levels of (nor)metanephrine and 3MT.
RESULTS: Plasma free 3MT levels were increased in 35 of the 124 patients (28%), whereas 24-h urinary excretion of deconjugated 3MT was increased in 30 patients (24%) (P=0.13). Plasma free MN levels were increased in seven patients (6%) and urinary deconjugated MN levels in six patients (5%) (P=1.00). Plasma free normetanephrine (NMN) levels were increased in seven patients (6%), and five patients had increased urinary excretion of deconjugated NMN (4%) (P=0.69). Plasma free combined MN levels (NMN, MN, and 3MT) were increased in 41 patients (33%), whereas 24-h urinary excretion rates of deconjugated combined MNs were increased in 33 patients (27%, P<0.05).
CONCLUSIONS: The combined levels of free MNs and free 3MT in plasma indicate a higher number of biochemically active HNPGLs than the 24-h urinary excretion rates of these markers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23832865     DOI: 10.1530/EJE-13-0529

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  22 in total

Review 1.  Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Authors:  Thamara E Osinga; Thera P Links; Robin P F Dullaart; Karel Pacak; Anouk N A van der Horst-Schrivers; Michiel N Kerstens; Ido P Kema
Journal:  FASEB J       Date:  2017-03-06       Impact factor: 5.191

Review 2.  Current approaches and recent developments in the management of head and neck paragangliomas.

Authors:  David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak
Journal:  Endocr Rev       Date:  2014-07-17       Impact factor: 19.871

Review 3.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

4.  Characterization of Malignant Head and Neck Paragangliomas at a Single Institution Across Multiple Decades.

Authors:  Hilary C McCrary; Eric Babajanian; Matias Calquin; Patrick Carpenter; Geoffrey Casazza; Anne Naumer; Samantha Greenberg; Wendy Kohlmann; Richard Cannon; Marcus M Monroe; Jason P Hunt; Luke Buchmann
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2019-07-01       Impact factor: 6.223

Review 5.  PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.

Authors:  Garima Gupta; Karel Pacak
Journal:  Endocr Pract       Date:  2017-03-23       Impact factor: 3.443

6.  A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas.

Authors:  A Guha; Z Musil; A Vicha; T Zelinka; K Pacak; J Astl; M Chovanec
Journal:  Neoplasma       Date:  2019-06-29       Impact factor: 2.575

7.  Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study.

Authors:  Henrique Vara Luiz; Mary Jane Tanchee; Maria G Pavlatou; Run Yu; Joan Nambuba; Katherine Wolf; Tamara Prodanov; Robert Wesley; Karen Adams; Tito Fojo; Karel Pacak
Journal:  Clin Endocrinol (Oxf)       Date:  2016-04-15       Impact factor: 3.478

Review 8.  Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing.

Authors:  Graeme Eisenhofer; Barbara Klink; Susan Richter; Jacques Wm Lenders; Mercedes Robledo
Journal:  Clin Biochem Rev       Date:  2017-04

Review 9.  International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers.

Authors:  Laurence Amar; Karel Pacak; Olivier Steichen; Scott A Akker; Simon J B Aylwin; Eric Baudin; Alexandre Buffet; Nelly Burnichon; Roderick J Clifton-Bligh; Patricia L M Dahia; Martin Fassnacht; Ashley B Grossman; Philippe Herman; Rodney J Hicks; Andrzej Januszewicz; Camilo Jimenez; Henricus P M Kunst; Dylan Lewis; Massimo Mannelli; Mitsuhide Naruse; Mercedes Robledo; David Taïeb; David R Taylor; Henri J L M Timmers; Giorgio Treglia; Nicola Tufton; William F Young; Jacques W M Lenders; Anne-Paule Gimenez-Roqueplo; Charlotte Lussey-Lepoutre
Journal:  Nat Rev Endocrinol       Date:  2021-05-21       Impact factor: 43.330

10.  Genetic Variants in Patients with Multiple Head and Neck Paragangliomas: Dilemma in Management.

Authors:  Anasuya Guha; Ales Vicha; Tomas Zelinka; Zdenek Musil; Martin Chovanec
Journal:  Biomedicines       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.